Major clinical progress of rheumatic disease in 2015

doi:10.3969/j.issn.1004-583X.2016.02.006

Abstract

Abstract: The clinical progress of rheumatic disease mainly concentrated in the change of management guidelines and treatment strategies in rheumatoid arthritis, rheumatic polymyalgia, IgG4 related disease and psoriasis arthritis during 2015. At the same time, the diagnostic criteria of primary Sjogren syndrome and gout were updated. The guidelines of systemic lupus erythematous (SLE) -associated pulmonary arterial hypertension were made, and our domestic rheumatologists made management suggestions for SLE patients during pregnancy and the puerperium. Both rheumatism itself and comorbidity attracted attention to in 2015, especially rheumatic diseases complicated with cardiovascular disease, and patient educations were more emphasized.

Key words: rheumatic diseases, arthritis,rheumatoid, rheumatic polymyalgia, gout, arthritis,psoriatic

CLC Number:

R593.21

Gao Lixia, Guo Huifang. Major clinical progress of rheumatic disease in 2015[J]. Clinical Focus, 2016, 31(2): 156-161.

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2016.02.006

https://huicui.hebmu.edu.cn/EN/Y2016/V31/I2/156

References

[1] Gibson DS, Bustard MJ, McGeough CM, et al. Current and future trends in biomarker discovery and development of companion diagnostics for arthritis[J]. Expert Rev Mol Diagn, 2015,15(2):219-234.
[2] Breedveld F. TNF antagonists opened the way to personalized medicine in rheumatoid arthritis[J]. Mol Med ,2014,20(Suppl 1):S7-9.
[3] Huizinga TW. Personalized medicine in rheumatoid arthritis: is the glass half full or half empty? [J]J Intern Med, 2015,277(2):178-187.
[4] Woodworth TG, den Broeder AA. Treating to target in established rheumatoid arthritis: challenges and opportunities in an era of novel targeted therapies and biosimilars[J]. Best Pract Res Clin Rheumatol, 2015,29(4/5):543-549.
[5] Abasolo L, Leon L, Rodriguez-Rodriguez L, et al. Safety of disease-modifying antirheumatic drugs and biologic agents for rheumatoid arthritis patients in real-life conditions[J]. Semin Arthritis Rheum, 2015,44(5):506-513.
[6] Barber CE, Smith A, Esdaile JM, et al. Best practices for cardiovascular disease prevention in rheumatoid arthritis: a systematic review of guideline recommendations and quality indicators[J]. Arthritis Care Res (Hoboken),2015,67(2):169-179.
[7] Ikdahl E, Rollefstad S, Olsen IC, et al. EULAR task force recommendations on annual cardiovascular risk assessment for patients with rheumatoid arthritis: an audit of the success of implementation in a rheumatology outpatient clinic[J]. Biomed Res Int, 2015,2015:515280.
[8] Mirabelli G, Cannarile F, Bruni C,et al. One year in review 2015: systemic lupus erythematosus[J]. Clin Exp Rheumatol, 2015,33(3):414-425.
[9] Willis R, Seif AM, McGwin G, et al. Effects of statins on proinflammatory/prothrombotic biomarkers and on disease activity scores in SLE patients: data from LUMINA (LXXVI), a multi-ethnic US cohort[J]. Clin Exp Rheumatol, 2014,32(2):162-167.
[10] No authors. Abstracts of the 11th International Congress on Systemic Lupus Erythematosus, September 2-6, 2015, Vienna, Austria[J]. Clin Exp Rheumatol, 2015,33(3 Suppl 90):S3-S82.
[11] Strand V, Petri M, Kalunian K, et al. Epratuzumab for patients with moderate to severe flaring SLE: health-related quality of life outcomes and corticosteroid use in the randomized controlled ALLEVIATE trials and extension study SL0006[J]. Rheumatology (Oxford),2014,53(3):502-511.
[12] Wang Z, Wang Y, Zhu R, et al. Long-term survival and death causes of systemic lupus erythematosus in China: a systemic review of observational studies[J]. Medicine (Baltimore),2015,94(17):e794.
[13] 国家风湿病数据中心,中国系统性红斑狼疮研究协作组.中国成人系统性红斑狼疮相关肺动脉高压诊治共识[J].中华内科杂志,2015,54(1): 81-86.
[14] 中国系统性红斑狼疮研究协作组专家组国家风湿病数据中心.中国系统性红斑狼疮患者围产期管理建议[J]. 中华医学杂志,2015,95(14)1050-1060.
[15] Hernandez-Molina G, Avila-Casado C, Nunez-Alvarez C, et al. Utility of the American-European Consensus Group and American College of Rheumatology Classification Criteria for Sjgren's syndrome in patients with systemic autoimmune diseases in the clinical setting[J]. Rheumatology (Oxford), 2015,54(3):441-448.
[16] Takagi Y, Sumi M, Nakamura H, et al. Ultrasonography as an additional item in the American College of Rheumatology classification of Sjgren's syndrome[J]. Rheumatology (Oxford),2014,53(11):1977-1983.
[17] Ma＇slińska M, Przygodzka M, Kwiatkowska B,et al. Sjgren's syndrome: still not fully understood disease[J]. Rheumatol Int, 2015,35(2):233-241.
[18] Khosroshahi A, Wallace ZS, Crowe JL, et al. International consensus guidance statement on the management and treatment of IgG4-related disease[J]. Arthritis Rheumatol,2015,67(7):1688-1699.
[19] Gossec L, Smolen JS. Treatment of psoriatic arthritis: management recommendations[J]. Clin Exp Rheumatol,2015,33(5 Suppl 93):S73-S77.
[20] Gossec L, Smolen JS, Ramiro S, et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update[J]. Ann Rheum Dis,2015 Dec 7.
[21] Colebatch-Bourn AN, Conaghan PG, Arden NK,et al. Raising the quality of rheumatology management recommendations: lessons from the EULAR process 10 years after provision of standard operating procedures[J]. Rheumatology (Oxford),2015,54(8):1392-1396.
[22] Neogi T, Jansen TL, Dalbeth N, et al. 2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative[J]. Ann Rheum Dis, 2015,74(10):1789-1798.
[23] Dejaco C, Singh YP, Perel P, et al. 2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative[J]. Ann Rheum Dis, 2015,74(10):1799-1807.
[24] Kerola AM, Kauppi MJ, Nieminen T, et al. Psychiatric and cardiovascular comorbidities as causes of long-term work disability among individuals with recent-onset rheumatoid arthritis[J]. Scand J Rheumatol,2015,44(2):87-92.
[25] Zangi HA, Ndosi M, Adams J, et al. EULAR recommendations for patient education for people with inflammatory arthritis[J]. Ann Rheum Dis,2015,74(6):954-962.